Rising Strategic Alliance for Development of Novel Protein Therapeutics

Released on: January 28, 2014, 9:48 am
Industry: Healthcare

-- /EPR NETWORK/ -- Acquisitions, collaborations and joint ventures are building up in the global protein therapeutics market to fuel further development. Market players are entering into such strategic activity to primarily build up on the resources available to them and gain faster research outcomes by utilizing technical skills of other market players. Recently, Novo Nordisk announced plans to collaborate with JDRF to discover and develop novel immunotherapies to treat and cure diabetes. Monoclonal antibody based therapeutics in particular are prominently gaining share in such activities.

Research Analysis & Highlights

Increasing patient base and constant investment by major pharma players will continue to boost the Protein Therapeutics market which may reach the mark of US$ 165 Billion by 2018. According to our new research report, “Global Protein Therapeutics Market Outlook 2018”, the growth within the market can also be attributed to increasing disposable income of the individuals and better delivery modes that are being developed.

The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performance and last but not the least, current and future market size. Moreover, the report provides a brief summary of the recent trends that may have an impact on the future industry performance. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.

Some of the key findings of the report are:

- Therapeutic Protein Players Investing Heavily in Multiple Sclerosis and Cancer
- Effective Delivery Modes Enhancing Patient Base of Therapeutic Proteins
- Huge Number of mAbs in Advanced Phase Clinical Trial to Accelerate Growth in Therapeutic Proteins

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM654.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

Contact-Details: B-129, Sector 6 Noida - 201301

WORD not available PDF not available PRINT not available

Back to previous page
Home page
Submit your press release